Tributary Capital Management Boosted By $324,000 Its Splunk (SPLK) Position; Shorts at Atyr Pharma (LIFE) Raised By 10.98%

Splunk Inc. (NASDAQ:SPLK) Logo

Atyr Pharma Inc (NASDAQ:LIFE) had an increase of 10.98% in short interest. LIFE’s SI was 1.15M shares in January as released by FINRA. Its up 10.98% from 1.04M shares previously. With 894,700 avg volume, 1 days are for Atyr Pharma Inc (NASDAQ:LIFE)’s short sellers to cover LIFE’s short positions. The SI to Atyr Pharma Inc’s float is 6.09%. The stock increased 1.04% or $0.0057 during the last trading session, reaching $0.5536. About 78,139 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has declined 85.23% since January 9, 2018 and is downtrending. It has underperformed by 85.23% the S&P500. Some Historical LIFE News: 14/05/2018 – Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean $LIFE @AmberTongPW; 08/05/2018 – aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018; 19/03/2018 – ATYR PHARMA INC QTRLY SHR LOSS $0.39; 15/05/2018 – Rock Springs Capital Management Exits Position in Atyr Pharma; 17/05/2018 – aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International; 02/05/2018 – aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting; 19/03/2018 – aTyr Pharma 4Q Loss $11.5M; 17/05/2018 – ATyr Pharma Presents Poster on Preclinical Data From ATYR1923 Program at Amer Thoracic Society 2018 Intl Conference; 14/05/2018 – aTyr Pharma 1Q Loss $10.7M; 14/05/2018 – ATyr Pharma Corporate Restructuring Includes Immediate 30% Workforce Reduction, Other Cost-Saving Measures

Tributary Capital Management Llc increased Splunk Inc (SPLK) stake by 20.77% reported in 2018Q3 SEC filing. Tributary Capital Management Llc acquired 2,700 shares as Splunk Inc (SPLK)’s stock declined 13.50%. The Tributary Capital Management Llc holds 15,700 shares with $1.90M value, up from 13,000 last quarter. Splunk Inc now has $17.20B valuation. The stock increased 1.09% or $1.26 during the last trading session, reaching $116.35. About 800,598 shares traded. Splunk Inc. (NASDAQ:SPLK) has risen 34.57% since January 9, 2018 and is uptrending. It has outperformed by 34.57% the S&P500. Some Historical SPLK News: 12/04/2018 – Nexthink Announces Integration With Splunk; 09/04/2018 – SPLUNK CLOSES PURCHASE OF PHANTOM; 08/03/2018 – Tech Today: Apple for Snap? Hiking Micron Numbers, Splunk M&A Bait? — Barron’s Blog; 24/05/2018 – SPLUNK 1Q REV. $311.6M, EST. $297.5M; 24/05/2018 – Splunk Had Seen 2019 Revenue $1.625 Billion; 24/04/2018 – Splunk Customers Accelerate Business Value Through Artificial Intelligence; 24/05/2018 – Splunk Raises 2019 View To Rev $1.645B; 12/03/2018 – “Mad Money” host Jim Cramer sits down with Splunk President and CEO Doug Merritt for the latest on his analytics company’s disruptive story; 24/05/2018 – SPLUNK INC SPLK.O FY2019 REV VIEW $1.63 BLN — THOMSON REUTERS l/B/E/S; 09/04/2018 – Splunk: Aggregate Purchase Price for Transaction Approximately $350 Million

More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: which released: “How SHOULD Income Annuities Be Taxed? – Nasdaq” on January 07, 2019, also with their article: “Buy These 3 MassMutual Funds for Great Returns – Nasdaq” published on January 09, 2019, published: “Japan Approves Amgen/UCB’s Osteoporosis Drug – Will U.S. Follow Suit? – Nasdaq” on January 09, 2019. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: and their article: “Setting Client Expectations And Defusing Time Bombs – Nasdaq” published on January 08, 2019 as well as‘s news article titled: “Ageas and BlackRock: Transparency notification – – Nasdaq” with publication date: January 09, 2019.

Among 2 analysts covering aTyr Pharma (NASDAQ:LIFE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. aTyr Pharma had 2 analyst reports since August 15, 2018 according to SRatingsIntel. BMO Capital Markets maintained aTyr Pharma, Inc. (NASDAQ:LIFE) rating on Wednesday, August 15. BMO Capital Markets has “Market Perform” rating and $1 target. Citigroup upgraded aTyr Pharma, Inc. (NASDAQ:LIFE) on Friday, August 17 to “Neutral” rating.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $16.62 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

Among 16 analysts covering Splunk (NASDAQ:SPLK), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Splunk had 17 analyst reports since July 10, 2018 according to SRatingsIntel. Deutsche Bank maintained Splunk Inc. (NASDAQ:SPLK) rating on Friday, August 24. Deutsche Bank has “Buy” rating and $140 target. The company was maintained on Friday, August 24 by Wedbush. The stock has “Outperform” rating by Credit Suisse on Friday, August 24. The company was maintained on Thursday, August 16 by Bank of America. Evercore downgraded the stock to “In-Line” rating in Tuesday, July 10 report. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, August 24 report. The stock of Splunk Inc. (NASDAQ:SPLK) has “Outperform” rating given on Friday, August 24 by Robert W. Baird. On Tuesday, November 6 the stock rating was downgraded by Bernstein to “Market Perform”. Morgan Stanley maintained the shares of SPLK in report on Friday, August 24 with “Equal-Weight” rating. The rating was maintained by Raymond James with “Outperform” on Friday, August 24.

Tributary Capital Management Llc decreased Methode Electronics (NYSE:MEI) stake by 34,481 shares to 410,320 valued at $14.85 million in 2018Q3. It also reduced Quanta Svcs Inc Com (NYSE:PWR) stake by 53,465 shares and now owns 62,675 shares. Marcus & Millichap (NYSE:MMI) was reduced too.

Investors sentiment decreased to 1.28 in Q3 2018. Its down 0.07, from 1.35 in 2018Q2. It is negative, as 32 investors sold SPLK shares while 141 reduced holdings. 94 funds opened positions while 128 raised stakes. 125.54 million shares or 0.80% less from 126.55 million shares in 2018Q2 were reported. Signaturefd Ltd Liability invested in 298 shares or 0% of the stock. Fdx Advisors stated it has 0.01% of its portfolio in Splunk Inc. (NASDAQ:SPLK). Reliance Of Delaware stated it has 8,667 shares. Baystate Wealth Limited owns 50 shares. Hanson Mcclain Inc reported 0% in Splunk Inc. (NASDAQ:SPLK). Commerzbank Aktiengesellschaft Fi has invested 0.02% in Splunk Inc. (NASDAQ:SPLK). Fiera Cap holds 0.25% or 512,668 shares in its portfolio. The Alabama-based Regions Fincl has invested 0% in Splunk Inc. (NASDAQ:SPLK). Prescott Group Mgmt Ltd Com reported 0.38% of its portfolio in Splunk Inc. (NASDAQ:SPLK). Primecap Mgmt Co Ca holds 0.58% in Splunk Inc. (NASDAQ:SPLK) or 7.10 million shares. 37,381 are held by Bnp Paribas Arbitrage Sa. Advsrs Asset Mngmt accumulated 15,771 shares or 0.03% of the stock. Dekabank Deutsche Girozentrale reported 311,074 shares. Parallax Volatility Advisers Limited Partnership stated it has 12,460 shares or 0% of all its holdings. Credit Suisse Ag invested in 0.12% or 1.08M shares.

Splunk Inc. (NASDAQ:SPLK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.